RevM10/polAS transduced hematopoietic stem cells(Systemix)(RevM10/polAS transduced hematopoietic stem cells(Systemix))

概要

基本信息

药物类型

基因疗法

别名-

靶点-

作用机制

基因转移

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

非霍奇金淋巴瘤

原研机构

Systemix, Inc.

在研机构-

非在研机构

Systemix, Inc.

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 RevM10/polAS transduced hematopoietic stem cells(Systemix) 相关的临床试验

NCT00003942 / Unknown status临床1/2期

A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support

RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of RevM10-treated stem cells plus chemotherapy and peripheral stem cell transplantation in treating patients who have HIV-related non-Hodgkin's lymphoma.

开始日期1998-11-01

申办/合作机构

Systemix, Inc.

[+1]

100 项与 RevM10/polAS transduced hematopoietic stem cells(Systemix) 相关的临床结果

登录后查看更多信息

100 项与 RevM10/polAS transduced hematopoietic stem cells(Systemix) 相关的转化医学

登录后查看更多信息

100 项与 RevM10/polAS transduced hematopoietic stem cells(Systemix) 相关的专利（医药）

登录后查看更多信息

100 项与 RevM10/polAS transduced hematopoietic stem cells(Systemix) 相关的药物交易

登录后查看更多信息